Caris Life Sciences ® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “CAI.”

Suraksha Diagnostic Ltd, an integrated diagnostic chain based in Kolkata, has successfully raised ₹254 crore from anchor investors ahead of its initial public offering (IPO). This significant funding comes just a day before the company opens its IPO for public subscription. The IPO is set to attract considerable attention, given the robust backing from prominent mutual funds and the company’s extensive operational network.